Reviva Pharmaceuticals Holdings Prices $5 Million Offering

MT Newswires Live08-21

Reviva Pharmaceuticals (RVPH) said Wednesday it had priced a $5 million offering of 4.8 million shares of common stock and 4.8 million warrants at a combined price of $1.05.

The company said the warrants have an exercise price of $0.7964 per share, exercisable immediately, and expire in five years.

The proceeds from the offering, expected to close on Aug. 22, would be used to fund research, including a Phase 3 trial and general corporate needs.

The drug developer said it would amend existing warrants issued to the investor in November 2023 and June 2021 to a reduced exercise price of $0.7964 per share with a five-year expiration.

Shares of the company fell more than 14% in premarket activity.

Price: 0.9750, Change: -0.16, Percent Change: -14.47

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2461684915?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-08-21 19:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2461684915","market":"hk","top_or_hot":-1,"title":"Reviva Pharmaceuticals Holdings Prices $5 Million Offering","media":"MT Newswires Live","content":"<html><body><p> Reviva Pharmaceuticals (RVPH) said Wednesday it had priced a $5 million offering of 4.8 million shares of common stock and 4.8 million warrants at a combined price of $1.05.</p><p>The company said the warrants have an exercise price of $0.7964 per share, exercisable immediately, and expire in five years.</p><p>The proceeds from the offering, expected to close on Aug. 22, would be used to fund research, including a Phase 3 trial and general corporate needs.</p><p>The drug developer said it would amend existing warrants issued to the investor in November 2023 and June 2021 to a reduced exercise price of $0.7964 per share with a five-year expiration.</p><p>Shares of the company fell more than 14% in premarket activity.</p><p>Price: 0.9750, Change: -0.16, Percent Change: -14.47</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Reviva Pharmaceuticals Holdings Prices $5 Million Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nReviva Pharmaceuticals Holdings Prices $5 Million Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-21 19:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Reviva Pharmaceuticals (RVPH) said Wednesday it had priced a $5 million offering of 4.8 million shares of common stock and 4.8 million warrants at a combined price of $1.05.The company said the ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RVPH","symbol_name":"Reviva Pharmaceuticals Holdings, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2461684915","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2461684915","pubTimestamp":1724238313,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Reviva Pharmaceuticals  said Wednesday it had priced a $5 million offering of 4.8 million shares of common stock and 4.8 million warrants at a combined price of $1.05.The company said the warrants have an exercise price of $0.7964 per share, exercisable immediately, and expire in five years.The proceeds from the offering, expected to close on Aug. 22, would be used to fund research, including a Phase 3 trial and general corporate needs.The drug developer said it would amend existing warrants issued to the investor in November 2023 and June 2021 to a reduced exercise price of $0.7964 per share with a five-year expiration.Shares of the company fell more than 14% in premarket activity.Price: 0.9750, Change: -0.16, Percent Change: -14.47","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RVPH":"Reviva Pharmaceuticals Holdings, Inc.","BK4007":"制药"},"translate_title":"Reviva Pharmaceuticals Holdings发行价格为500万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RVPH":0.9},"content_text":"Reviva Pharmaceuticals (RVPH) said Wednesday it had priced a $5 million offering of 4.8 million shares of common stock and 4.8 million warrants at a combined price of $1.05.The company said the warrants have an exercise price of $0.7964 per share, exercisable immediately, and expire in five years.The proceeds from the offering, expected to close on Aug. 22, would be used to fund research, including a Phase 3 trial and general corporate needs.The drug developer said it would amend existing warrants issued to the investor in November 2023 and June 2021 to a reduced exercise price of $0.7964 per share with a five-year expiration.Shares of the company fell more than 14% in premarket activity.Price: 0.9750, Change: -0.16, Percent Change: -14.47","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2461684915"}